LXRP - Lexaria Bioscience Continues to Grow its Patent Portfolio
(TheNewswire)
Kelowna, British Columbia - TheNewswire - September 22, 2020 - Lexaria Bioscience Corp. (OTC:LXRP) (CSE:LXX) (CNSX:LXX.CN) (the "Company"or "Lexaria"), a global innovator in drug deliveryplatforms, is pleased to announces that it has received another new granted patent in theUSA.
Lexaria has been granted U.S. Patent No.10,756,180 pursuant to the Notice of Allowance it received from theUnited States Patent and Trademark Office("USPTO") for patent application number16/497,920 previously announced on April 23, 2020.
This new patent provides patent claimsthat protect the use of Lexaria's DehydraTECH(TM) technology togetherwith cannabinoids, nicotine, nonsteroidal anti-inflammatory drugs, orvitamins in mix and serve beverage formats. The patent isentitled "Food and Beverage Compositions Infused With LipophilicActive Agents and Methods of Use Thereof". This signifiesanother addition to Lexaria's first patent family, under which nineUS patents have now been granted.
Lexaria has also responded to patent office queries inEurope, India, Mexico, Australia, USA, Japan and Canada in recentweeks and although the Company does not expect all its applications tobe successful, it is optimistic of additional patent grants in some ofthese locations soon.
Lexaria currently has 17 granted patents, with 9granted in the US and 8 in Australia, along with roughly 60 patentapplications pending throughout the world. The granted patents coverdelivery of cannabinoids, NSAIDs, nicotine and fat-soluble vitamins.Patents are pending for the delivery of antiviral drugs, humanhormones such as testosterone and estrogen, phosphodiesteraseinhibitors and more.
About Lexaria
Lexaria Bioscience Corp.'s (OTCQX: LXRP, CSE: LXX)proprietary drug delivery technology, DehydraTECH(TM), improves theway active pharmaceutical ingredients (APIs) enter the bloodstream bypromoting healthier ingestion methods and increasing the effectivenessof fat-soluble active molecules, thereby lowering overall dosing. TheCompany's technology can be applied to many different ingestibleproduct formats, including foods, beverages, oral suspensions,tablets, and capsules. DehydraTECH increases bio-absorption by up to5-10x, reduces time of onset from 1 - 2 hours to 10 - 20 minutes, andmasks unwanted tastes for orally administered bioactive molecules,including anti-virals, cannabinoids, vitamins, non-steroidalanti-inflammatory drugs (NSAIDs), nicotine, and other molecules.Lexaria has licensed DehydraTECH to multiple companies including aworld-leading tobacco producer for the development of smokeless,oral-based nicotine products and for use in industries that producecannabinoid beverages, edibles, and oral products. Lexaria operates alicensed in-house research laboratory and holds a robust intellectualproperty portfolio with 16 patents granted and over 60 patents pendingworldwide. For more information, please visit www.lexariabioscience.com.
FORWARD-LOOKINGSTATEMENTS
This release includes forward-looking statements. Statements as suchterm is defined under applicable securities laws. These statements maybe identified by words such as "anticipate," "if,""believe," "plan," "estimate,""expect," "intend," "may,""could," "should," "will," and othersimilar expressions. Such forward-looking statements in this pressrelease include, but are not limited to, all statements by the companyrelated to patents granted or pending. Such forward-looking statementsare estimates reflecting the Company's best judgment based uponcurrent information and involve a number of risks and uncertainties,and there can be no assurance that the Company will actually achievethe plans, intentions, or expectations disclosed in theseforward-looking statements. As such, you should not place unduereliance on these forward-looking statements. Factors which couldcause actual results to differ materially from those estimated by theCompany include, but are not limited to, government regulation andregulatory approvals, managing and maintaining growth, the effect ofadverse publicity, litigation, competition, scientific discovery, thepatent application and approval process, potential adverse effectsarising from the testing or use of products utilizing the DehydraTECHtechnology, the Company's ability to maintain existing collaborationsand realize the benefits thereof, and other factors which may beidentified from time to time in the Company's public announcements andperiodic filings with the US Securities and Exchange Commission onEDGAR. There is no assurance that existing capital is sufficient forthe Company's needs or that it will be able to raise additionalcapital. There is no assurance the Company will be capable ofdeveloping, marketing, licensing, or selling edible productscontaining any active ingredient. There is no assurance that anyplanned corporate activity, scientific research or study, businessventure, letter of intent, technology licensing pursuit, patentapplication or allowance, consumer study, or any initiative will bepursued, or if pursued, will be successful. There is no assurance thatany of Lexaria's postulated uses, benefits, or advantages for thepatented and patent-pending technology will in fact be realized in anymanner or in any part. No statement herein has been evaluated by theFood and Drug Administration (FDA). Lexaria-associated products arenot intended to diagnose, treat, cure or prevent any disease.
Any forward-looking statements contained in this release speak only asof the date hereof, and the Company expressly disclaims any obligationto update any forward-looking statements contained herein, whether asa result of any new information, future events, changed circumstancesor otherwise, except as otherwise required by law.
The CSE has notreviewed and does not accept responsibility for the adequacy oraccuracy of this release.
INVESTOR CONTACT:
Phone: 866-221-3341
Copyright (c) 2020 TheNewswire - All rights reserved.